Evidence map›Paper›PMID 30911675›Full record

ArticleNPJ breast cancer2019

AKT1

Sheheryar Kabraji, Xaiver Sole, Ying Huang, Clyde Bango, Dennis Sgroi, Massimo Loda, Sridhar Ramaswamy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Diversity and molecular network patterns of symptom phenotypes.NPJ systems biology and applications · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sheheryar Kabraji *1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215 USA.
Xaiver Sole *2Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain.
Ying Huang3Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA 02215 USA.
Clyde Bango3Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA 02215 USA.
Dennis Sgroi4Department of Pathology, Massachusetts General Hospital, Boston, MA 02114 USA.
Massimo Loda3Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA 02215 USA.
Sridhar Ramaswamy5Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114 USA.
Dana-Farber Cancer Institute · USMassachusetts General Hospital · USInstitut Català d'Oncologia · ES

Funding

(PQC6) Molecular Determinants of Quiescent Cancer CellsR01CA185086 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI VASUDEVAN, SHOBHA · 2014 to 2017
$1.8M
NCI NIH HHS R01 CA185086
6 · The paper itself

Abstract

Ductal carcinoma in situ (DCIS) of the breast precedes the development of invasive breast cancer and reflects the genomic changes and protein expression profile of invasive disease. AKT1

Identifiers

PMID30911675
PMCPMC6428812
OpenAlexW2924943458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.